Golimumab treatment provides superior treatment of rheumatoid arthritis
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trialLancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
461 patients with rheumatoid arthritis who have undergone treatment with a TNF-alpha inhibitor previously were randomized to three groups. 2 groups were treated with either a 50 mg or 100 mg dosage of Golimumab and the third group received a placebo injection. The results indicated that treatment with Golimumab at either dose provided significant improvements in rheumatoid arthritis measures (ARC2...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE